Spyre Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
221 Crescent St Ste 105, Waltham, Massac...Phone Number
(617) 651-5940Website
www.spyre.comRevenue
-Stock Symbol
SYREIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Spyre Therapeutics
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapies for individuals living with inflammatory bowel disease and other immune-mediated disorders. The company focuses on advancing next-generation biologic medicines designed to address significant unmet medical needs by improving treatment effectiveness, durability, and patient outcomes. Its research strategy combines advanced antibody engineering, optimized therapeutic design, and carefully selected combination therapies to develop treatments intended to provide more comprehensive control of chronic inflammatory diseases.Explore more
Spyre Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spyre Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Spyre Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Spyre Therapeutics launches new products
Funding: Get notified immidiatlly once Spyre Therapeutics has new funding data
Click to see if Spyre Therapeutics had a recent Job posting/layoffs
Check if Spyre Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Spyre Therapeutics
Earning: See what the market has to say on Spyre Therapeutics recently announced quarterly report
Check out if Spyre Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Spyre Therapeutics
Find 2 more new buyers
Compare Similar Companies to Spyre Therapeutics
Compare insights from companies similar to Spyre Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Spyre Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Spyre Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Spyre Therapeutics.
Spyre Therapeutics Tech Stack
A closer look at the technologies used by Spyre Therapeutics
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Spyre Therapeutics News & Media
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
SPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulationSpyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase aSpyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know
This disposition follows a staggering 500% one-year stock surge.A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know
This sale was executed under a pre-arranged plan as the stock posted a staggering return over 12 months.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Spyre Therapeutics
Sign Up For FreeTo access detailed company insights
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapies for individuals living with inflammatory bowel disease and other immune-mediated disorders. The company focuses on advancing next-generation biologic medicines designed to address significant unmet medical needs by i... Read More
